158 related articles for article (PubMed ID: 3479115)
1. Remission of rheumatoid arthritis with the successful treatment of acute myelogenous leukemia with cytosine arabinoside, daunorubicin, and m-AMSA.
Roubenoff R; Jones RJ; Karp JE; Stevens MB
Arthritis Rheum; 1987 Oct; 30(10):1187-90. PubMed ID: 3479115
[TBL] [Abstract][Full Text] [Related]
2. Intermediate-dose Ara-C/m-AMSA for remission induction and high-dose Ara-C/m-AMSA for intensive consolidation in relapsed and refractory adult acute myelogeneous leukemia.
Jehn U; Heinemann V
Haematol Blood Transfus; 1990; 33():333-8. PubMed ID: 1691134
[TBL] [Abstract][Full Text] [Related]
3. Intensive treatment of acute leukemia in adults 70 years of age and older.
Walters RS; Kantarjian HM; Keating MJ; Estey EH; McCredie KB; Freireich EJ
Cancer; 1987 Jul; 60(2):149-55. PubMed ID: 3474052
[TBL] [Abstract][Full Text] [Related]
4. Results of induction and consolidation treatment with intermediate and high-dose cytosine arabinoside and m-Amsa of patients with poor-risk acute myelogenous leukaemia.
Peters WG; Willemze R; Colly LP
Eur J Haematol; 1988 Mar; 40(3):198-204. PubMed ID: 3162718
[TBL] [Abstract][Full Text] [Related]
5. Long-term follow-up of a randomized post-induction therapy trial in acute myelogenous leukemia (a Southeastern Cancer Study Group trial).
Volger WR; Weiner RS; Moore JO; Omura GA; Bartolucci AA; Stagg M
Leukemia; 1995 Sep; 9(9):1456-60. PubMed ID: 7544851
[TBL] [Abstract][Full Text] [Related]
6. Amsacrine and continuous-infusion high-dose cytosine arabinoside as induction therapy for patients with newly-diagnosed acute myelogenous leukemia.
Ghaddar HM; Pierce S; Kantarjian HM; Freireich EJ; Keating MJ; Estey EH
Leuk Lymphoma; 1996 Jun; 22(1-2):71-6. PubMed ID: 8724530
[TBL] [Abstract][Full Text] [Related]
7. Therapy of acute myelogenous leukemia in patients over the age of 50: a randomized Southeastern Cancer Study Group trial.
Stein RS; Vogler WR; Winton EF; Cohen HJ; Raney MR; Bartolucci A
Leuk Res; 1990; 14(10):895-903. PubMed ID: 2259226
[TBL] [Abstract][Full Text] [Related]
8. Intermediate-dose cytosine arabinoside and amsacrine. An effective regimen with low toxicity in refractory acute nonlymphocytic leukemia.
Dekker AW; Nieuwenhuis HK; Verdonck LF
Cancer; 1990 May; 65(9):1891-4. PubMed ID: 2372760
[TBL] [Abstract][Full Text] [Related]
9. A phase-three trial comparing daunorubicin or idarubicin combined with cytosine arabinoside in acute myelogenous leukemia.
Vogler WR; Velez-Garcia E; Omura G; Raney M
Semin Oncol; 1989 Feb; 16(1 Suppl 2):21-4. PubMed ID: 2648581
[No Abstract] [Full Text] [Related]
10. Aclarubicin plus cytosine arabinoside versus daunorubicin plus cytosine arabinoside in previously untreated patients with acute myeloid leukemia: a Danish national phase III trial. The Danish Society of Hematology Study Group on AML, Denmark.
Hansen OP; Pedersen-Bjergaard J; Ellegaard J; Brincker H; Boesen AM; Christensen BE; Drivsholm A; Hippe E; Jans H; Jensen KB
Leukemia; 1991 Jun; 5(6):510-6. PubMed ID: 2056774
[TBL] [Abstract][Full Text] [Related]
11. Intermediate and high-dose ARA-C and m-AMSA (or daunorubicin) as remission and consolidation treatment for patients with relapsed acute leukaemia and lymphoblastic non-Hodgkin lymphoma.
Willemze R; Peters WG; van Hennik MB; Fibbe WE; Kootte AM; van Berkel M; Lie R; Rodenburg CJ; Veltkamp JJ
Scand J Haematol; 1985 Jan; 34(1):83-7. PubMed ID: 3855571
[TBL] [Abstract][Full Text] [Related]
12. Intermediate-dose Ara-C/m-AMSA for remission induction and high-dose Ara-C/m-AMSA for intensive consolidation in relapsed and refractory adult acute myelogenous leukemia (AML).
Jehn U; Heinemann V; Wilmanns W
Anticancer Res; 1989; 9(1):119-24. PubMed ID: 2705739
[TBL] [Abstract][Full Text] [Related]
13. Intermediate and high dose Ara-C and m-AMSA for remission induction and consolidation treatment of patients with acute myeloid leukemia: an EORTC Leukemia Cooperative Group phase II study.
Willemze R; Jager U; Jehn U; Stryckmans P; Bury J; Suciu S; Solbu G; Zittoun R; Burghouts J; Löwenberg B
Eur J Cancer Clin Oncol; 1988 Nov; 24(11):1721-5. PubMed ID: 3061827
[TBL] [Abstract][Full Text] [Related]
14. [4'-(9-acridinylamino)-methanesulfon-m-aniside (AMSA) combination salvage therapy in refractory acute non-lymphocytic leukemia in adults].
Mukaiyama T; Ogawa M; Horikoshi N; Inoue K; Fukutani H; Tabata M; Hirano A; Mizunuma N; Itami S
Gan To Kagaku Ryoho; 1989 May; 16(5):2019-23. PubMed ID: 2730091
[TBL] [Abstract][Full Text] [Related]
15. High-dose cytosine arabinoside and amsacrine or mitoxantrone in relapsed and refractory acute myeloid leukaemia: a prospective randomized study.
Martiat P; Ghilain JM; Ferrant A; Doyen C; Delannoy A; Chatelain C; Bosly A; Michaux JL; Sokal G
Eur J Haematol; 1990 Sep; 45(3):164-7. PubMed ID: 2226729
[TBL] [Abstract][Full Text] [Related]
16. High-dose cytosine arabinoside and daunorubicin as primary therapy in elderly patients with acute myelogenous leukemia. A phase I-II study of the Southeastern Cancer Study Group.
Lazarus HM; Vogler WR; Burns CP; Winton EF
Cancer; 1989 Mar; 63(6):1055-9. PubMed ID: 2917307
[TBL] [Abstract][Full Text] [Related]
17. Remission induction and maintenance modalities in acute myeloid leukemia: a multicenter randomized study.
Marty M; Lepage E; Guy H; Bordessoule D; Desablens B; Harousseau JL; Guilhot F; Leverger G; Schaison G; Boiron M
Haematol Blood Transfus; 1987; 30():50-6. PubMed ID: 3305217
[No Abstract] [Full Text] [Related]
18. Amsacrine, cytarabine and thioguanine (AAT) versus daunorubicin, cytarabine, thioguanine (DAT) in adults with untreated acute non-lymphoblastic leukemia (ANLL). Austrian-German results.
Linkesch W; Michlmayr G; Gerhartz H; Illinger H; König H; Düllmann J; Keilhauer R; Moldrzyk D
Onkologie; 1989 Feb; 12(1):8-10. PubMed ID: 2654791
[TBL] [Abstract][Full Text] [Related]
19. [Combination of AMSA-high dose cytosine arabinoside in acute leukemia].
Zittoun R; Rio B; Marie JP; Blanc CM
Presse Med; 1985 Jun; 14(26):1417-20. PubMed ID: 3161047
[TBL] [Abstract][Full Text] [Related]
20. Successful re-induction therapy for acute myelogenous leukemia with cytosine arabinoside and daunorubicin.
Stein RS; Flexner JM
Cancer Treat Rep; 1979; 63(11-12):2123-4. PubMed ID: 294309
[No Abstract] [Full Text] [Related]
[Next] [New Search]